🟢 Inovio Pharmaceuticals is trading 5% up today amid possible anticipation of FDA decision

Inovio Pharmaceuticals is trading at $1.35, up +5.04%, amid possible anticipation of the FDA decision, although no direct catalyst is confirmed.

• No new company-specific announcement dated August 31, 2026 was identified.
• FDA review of INO-3107 is progressing toward the October 30, 2026 PDUFA date, with pre-licensure inspections completed.
• Major U.S. indices are declining, so the gain does not clearly track overall sentiment.